Proffitt & Goodson’s Lineage Cell Therapeutics LCTX Stock Holding History

Proffitt & Goodson’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17	Closed	–	–	255
2022 Q2	$0	Buy	+17	New	+$22	﹤0.01%	269

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Proffitt & Goodson's LCTX Position: Q3 2022 in Review

Proffitt & Goodson sold out of Lineage Cell Therapeutics (LCTX) in Q3 2022, closing a stake of 17 shares.

Proffitt & Goodson first reported a position in LCTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 105 funds tracked by Wall St. Rank hold LCTX as of Q3 2022.

Proffitt & Goodson reported no remaining Lineage Cell Therapeutics position as of Q3 2022 after selling out during the quarter.
Proffitt & Goodson sold 17 Lineage Cell Therapeutics shares in Q3 2022.
Proffitt & Goodson first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 1 quarter.
Proffitt & Goodson's Lineage Cell Therapeutics position peaked at $0 in Q2 2022.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2022.

Based on Proffitt & Goodson's 13F filing for Q3 2022, filed 24 Oct 2022.